Table 2.

Investigator assessed efficacy endpoints in arm A and arm B

Endpoint	Arm A	Arm B
	Median (95% CI)	Median (95% CI)	HR	P value
Progression-free survival (months)	6.6 (5.1–9.0)	5.6 (3.8–6.5)	1.80	0.041
Overall survival (months)	20.7 (16.4–26.7)	12.1 (5.8–20.4)	2.01	0.018
Time to Progression (months)	6.6 (5.1–9.0)	5.3 (3.8–6.5)	1.98	0.030
Time to next treatment (months)	7.4 (6.1–10.4)	7.0 (5.8–10.3)	1.38	0.334
	n(%);(95% CI)	n(%);(95% CI)		P value
Clinical control rate	28 (93.3) (77.6–99.2)	21 (70.0) (52.0–83.5)		0.020
Overall response rate	13 (43.3) (27.4–60.8)	12 (40) (24.6–57.7)		0.793